Article Text

PDF
Dexamethasone intravitreal implant in serpiginous choroiditis
  1. Elisabetta Miserocchi,
  2. Luigi Berchicci,
  3. Lorenzo Iuliano,
  4. Giulio Modorati,
  5. Francesco Bandello
  1. Department of Ophthalmology, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
  1. Correspondence to Dr Elisabetta Miserocchi, Ocular Immunology and Uveitis Service, Department of Ophthalmology, Vita-Salute University, San Raffaele Scientific Institute, Via Olgettina, 60, 20132 Milan, Italy; miserocchi.elisabetta{at}hsr.it

Abstract

Background/aims To assess the efficacy and safety of dexamethasone (DEX) intravitreal implant in patients with active serpiginous choroiditis (SC) already receiving maximal tolerated systemic immunosuppressive therapy.

Methods In this retrospective longitudinal study we evaluated patients receiving 0.7 mg DEX intravitreal implant for active SC despite maximal systemic immunosuppression. Medical history was reviewed over a period of 18 months for each patient. We diagnosed SC activity using direct fundus examination and blue-light fundus autofluorescence. Primary outcomes were the rate of disease control and functional changes at end of follow-up. Secondary outcomes were the incidence of injection-related adverse events and the success of immunosuppression tapering at the last examination.

Results We examined eight eyes of seven patients. We controlled SC activity with one injection in five eyes, two injections in one eye, and three injections in two eyes (total of 13 implants). Best-corrected visual acuity at the end of the investigational period improved in two eyes (25%), remained stable in four eyes (50%) and decreased in two eyes (25%). Three eyes showed transient intraocular pressure increase and two eyes disclosed cataract progression. The average dosage of systemic prednisone at baseline and after DEX intravitreal implant decreased from 8.8 to 2.8 mg/day.

Conclusions Dexamethasone intravitreal implant may be an effective treatment option to control active serpiginous lesions in patients in whom increased systemic corticosteroid therapy is contraindicated.

Statistics from Altmetric.com

Footnotes

  • Twitter Follow Lorenzo Iuliano at @loriul

  • Contributors Design of the study, critical revision of the article, final approval of the article and provision of materials, patients, or resources (EM, LB, GM and FB); analysis and interpretation (EM, GM, LI, LB and FB); writing of the article and administrative, technical, and logistic support (EM and LB); data collection (EM, LB, LI and GM); statistical expertise (LI); literature search (EM, GM and LB).

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval The Institutional Review Board of Scientific Institute San Raffaele, Milano, Italy.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Keith Barton James Chodosh Jost Jonas